Archive for the ‘Lyme’ Category

NPMA Emphasizes Tick Prevention Amidst New CDC Lyme Disease Estimates

https://pestworldmag.npmapestworld.org/2021/02/01/npma-emphasizes-tick-prevention-amidst-new-cdc-lyme-disease-estimates/

NPMA Emphasizes Tick Prevention Amidst New CDC Lyme Disease Estimates

The National Pest Management Association shares everything the public should know to guard against the serious tickborne disease

According to new research released by the Centers for Disease Control and Prevention (CDC), human cases of tickborne Lyme disease are more common in the U.S. than previously thought. Based on insurance records from 2010 to 2018, the CDC estimates that approximately 476,000 people were diagnosed with and treated for Lyme disease each year in the U.S., representing a staggering 44 percent increase compared to the previous annual estimate of about 329,000 people from 2005 to 2010. In the wake of this alarming uptick, the National Pest Management Association (NPMA) is reminding the public about the serious health threats posed by ticks and the safety precautions people should practice when spending time outdoors.

Blacklegged ticks, also known as deer ticks, are predominantly found in the Northeast region of the U.S.; however, human cases of Lyme disease, transmitted through the bite of infected blacklegged ticks, have been detected in all 50 states,” said Cindy Mannes, senior vice president of public affairs for the NPMA. “Proper tick prevention is crucial to our health and wellbeing, especially now as outdoor excursions like hikes have become the preferred socially-distanced activities amidst the ongoing pandemic.”

Although Lyme disease is treatable, it can easily be confused for other conditions and cases of the disease are vastly underreported. The CDC receives about 30,000 to 40,000 reported cases each year, much less than the 476,000 annual cases estimated in the agency’s recent report. Knowing the telltale signs of Lyme disease, such as a “bull’s-eye” rash that can appear in some cases, is essential to early detection and receiving proper care. However, the disease can present flu-like symptoms similar to those caused by the common cold or even COVID-19, so anyone experiencing these issues should alert their medical provider and be sure to note if they’ve recently been bitten by a tick.

“Lyme disease can cause a number of different symptoms, from fever and headaches to heart palpitations and brain inflammation,” explained Dr. Jorge Parada, M.D., M.P.H., F.A.C.P., F.I.D.S.A., F.S.H.E.A., medical advisor for the National Pest Management Association. “In addition to aiding in Lyme disease diagnosis, regular tick checks can actually help prevent disease transmission in the first place. Lyme disease can be transmitted into a person’s bloodstream in as little as 36-48 hours after the initial tick bite, making prompt detection and proper tick removal key to disease prevention.”

While peak tick season typically takes place during the warmer months, these pests can still pose serious threats even when the weather outside is cold. According to the CDC’s National Syndromic Surveillance Program, emergency department visits for tick bites typically experience a secondary spike during October and November. To stay safe and tick-free, follow these year-round prevention methods:

  • Wear long-sleeved shirts, long pants and closed-toed shoes
  • Wear insect repellent containing at least 20 percent DEET when outdoors
  • Inspect yourself, your family and pets for ticks after spending time outdoors

Wild animals such as deer can bring ticks onto personal property, where they can detach and hide amongst overgrown grass and vegetation. Regularly remove weeds and cut grass low to keep your yard tick-free, and contact a licensed pest control professional if you suspect or discover a tick infestation.

For more information about tick prevention and tickborne diseases, visit www.PestWorld.org.

https://pestworldmag.npmapestworld.org/2021/03/16/ppma-calls-for-industry-participation-during-inaugural-tick-awareness-week/

PPMA Calls for Industry Participation During Inaugural Tick Awareness Week

Pest control companies urged to help spread consumer awareness of the dangers associated with ticksIn recognition of its inaugural Tick Awareness Week

PPMA will also be unveiling an exciting new consumer campaign: TickTalk. The campaign will kick off during Tick Awareness Week with a comprehensive digital and media relations plan as well as a new microsite complete with never-before-seen photos and videos! PPMA also created an exclusive toolkit available for Mainframe subscribers to download on PPMAMainframe.org. The toolkit includes a customizable press release, suggested social media content, “Tick Talk” logos to be used as website badges, high-resolution photography and video content, and more.

About the National Pest Management Association 

The NPMA, a non-profit organization with more than 5,500 members, was established in 1933 to support the pest management industry’s commitment to the protection of public health, food and property from the diseases and dangers of pests. For more information, visit PestWorld.org or follow @PestWorld on Facebook, Twitter, Pinterest and YouTube.

_____________________

**Comment**

Ticks are already active.

Also, there are cases where transmission occurred much faster than the often quoted 36-48 hours, and minimum time has never been established.  

Speaking of transmission, ticks aren’t the only thing you must be concerned with (although authorities want to squash this intel like a June Bug): 

More on prevention:

Psychiatric Manifestations of Tick-Borne Infections: Dr. Bransfield

http://

March 12, 2021

Online Seminar: Robert Bransfield on Psychiatric Manifestations of Tick-Borne Infections

This online seminar took place on Friday 12 March 2021 and was facilitated by Julia Knight, our Press & Community Outreach Manager. Dr Bransfield discussed Lyme disease and tick borne infections from a psychiatric perspective and how these illnesses affect brain chemistry.

Dr Bransfield’s primary activity is an office based private practice of psychiatry. He is the Associate Director of Psychiatry and Chairman of Psychiatric Quality Assurance at Riverview Medical Center in Red Bank, NJ, Past Immediate President of the International Lyme and Associated Diseases Society, and Immediate President of the New Jersey Psychiatric Association.

Dr Bransfield has kindly shared his presentation with us, which is available for download here: Robert C Bransfield Chronic Neuropsychiatric Symptoms from Lyme/Tick-Borne Disease and COVID-19.

More by Dr. Bransfield:

Targeting Multicopy Prophage Genes for the Increased Detection of Borrelia burgdorferi Sensu Lato, the Causative Agents of Lyme Disease, in Blood

https://www.frontiersin.org/articles/10.3389/fmicb.2021.651217/full

ORIGINAL RESEARCH ARTICLE

Front. Microbiol., 15 March 2021 | https://doi.org/10.3389/fmicb.2021.651217

Targeting Multicopy Prophage Genes for the Increased Detection of Borrelia burgdorferi Sensu Lato (s.l.), the Causative Agents of Lyme Disease, in Blood

  • 1Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom
  • 2PhelixRD Charity 230 Rue du Faubourg St Honoré, Paris, France

The successful treatment of Lyme disease (LD) is contingent on accurate diagnosis. However, current laboratory detection assays lack sensitivity in the early stages of the disease. Because delayed diagnosis of LD incurs high healthcare costs and great suffering, new highly sensitive tests are in need. To overcome these challenges, we developed an internally controlled quantitative PCR (Ter-qPCR) that targets the multicopy terminase large subunit (terL) gene encoded by prophages that are only found in LD-causing bacteria. The terL protein helps phages pack their DNA. Strikingly, the detection limit of the Ter-qPCR was analytically estimated to be 22 copies and one bacterial cell in bacteria spiked blood. Furthermore, significant quantitative differences was observed in terms of the amount of terL detected in healthy individuals and patients with either early or late disease. Together, the data suggests that the prophage-targeting PCR has significant power to improve success detection for LD. After rigorous clinical validation, this new test could deliver a step-change in the detection of LD. Prophage encoded markers are prevalent in many other pathogenic bacteria rendering this approach highly applicable to bacterial identification in general.

Introduction

Lyme disease (LD) is the most common tick-born disease with approximately 476,000 patients in the United States annually during 2010–2018 (Kugeler et al., 2021). LD is caused by a group of bacteria classified together as the Borrelia burgdorferi sensu lato (s.l.) complex, that comprises a clade of more than 20 species including B. burgdorferisensu stricto (s.s.) which dominates in United States, and B. garinii and B. afzelii which are prevalent in Europe and Asia. The LD-causing bacteria are generally transmitted to humans after they are bitten by ticks of the Ixodes family infected with LD causing Borrelia. However, recent reports have raised concerns over Borrelia transmission through blood transfusion based on observations that Borrelia can survive and circulate in the human bloodstream (Pavia and Plummer, 2018).

Currently, LD diagnosis is based on the overt clinical manifestation of disease in the form of erythema migrans (EM) skin lesions, commonly known as a ‘bull’s-eye’ rash and a history of tick exposure. Although EM lesions occur in 70 to 80% of infected individuals, only a third of these patients develop the classic ‘bull’s-eye’ rash, and many other types of skin lesions can occur which are easily confused with EM (Chaaya et al., 2016). In addition to the EM uncertainty, other common symptoms of LD such as fatigue, muscle pain, headache, and perceived cognitive dysfunction largely overlap with an array of other diseases, including other tick-borne diseases. One such example is Relapsing Fever (RF), which is caused by close relatives of the LD-causing bacteria, such as Borrelia miyamotoi(Wormser et al., 2019). The two Borrelia ‘groups’ responsible for LD and RF have caused great concern and clinical confusion, as they are morphologically similar and present with almost indistinguishable clinical symptoms (Bergström and Normark, 2018). Despite this, they respond to different antibiotics and treatment regimens (Koetsveld et al., 2017). Another example of confusion surrounding LD is the co-infection caused by Bartonella spp. This genus of bacteria is emerging as an increasingly common human infection (Anderson and Neuman, 1997). Much of the controversy surrounding LD and co-infections with Bartonella and/or B. miyamotoi is due to the lack of a reliable and sensitive diagnostic method to detect and distinguish between the three groups of bacteria, the LD and RF causing Borrelia and Bartonella (Schutzer et al., 2019). Therefore, laboratory tests to determine and distinguish between LD and co-infections play a vital role in the correct diagnosis and consequent treatment with different antibiotics.

Scientists have faced several challenges with LD detection including patients presenting with a delayed antibody response and a low number of Borrelia cells typically found in human clinical samples (Moore et al., 2016). Although it is particularly difficult to diagnose LD early, it is critical, as it is far easier to treat the disease when it is detected at an early stage (Theel et al., 2019). Bacteria-targeting approaches, such as polymerase chain reaction (PCR) detecting the Borrelia chromosomal DNA, can potentially identify early LD but is relatively insensitive detecting only between 30-50% of positive cases, and is therefore deemed to have little clinical utility (Schutzer et al., 2019). The reasons behind the poor sensitivity of the current PCR methods in Lyme detection are twofold; first, the current PCRs target Borrelia genomic DNA regions that have only one copy in each bacterium, such as the bacterial 16S rRNA gene, RecA gene, and the 5S-23S intergenic regions (Brettschneider et al., 1998; Liveris et al., 2012; Waddell et al., 2016; Lohr et al., 2018; Schutzer et al., 2019). Second, at least some Borrelia species are ‘tissue-bound’ and are only transiently found circulating in the blood (Liang et al., 2020).

In response to these diagnostic challenges, we adopted a novel approach, taking advantage of the fact that most pathogenic bacteria carry multiple complete or partial prophages (phages associated with bacteria) (Argov et al., 2019). These prophage sequences can form the bases of a template from which quantitative PCR (qPCR) primers and probes can be designed. It is known that Borrelia carry a large number of linear and circular plasmids (comprising between 33-40% of the Borrelia genome), among which the cp26 and cp32, and the lp54 linear plasmid, are evolutionarily stable (Casjens et al., 2017). Of these paralogous plasmids, cp32 has been experimentally determined to be a Borrelia burgdorferi prophage thus it is highly likely that many of its homologs are also prophages (Eggers and Samuels, 2000).

In this paper we have demonstrated for the first time in Borrelia-related diagnostics that it is possible to overcome the sensitivity challenges associated with LD detection. We highlight the potential of our test to discriminate between healthy volunteers, early LD, and late LD patients. We present data from a systematic and comprehensive study that evaluate the use of the multicopy phage terminase large subunit (terL) gene as a molecular marker for the detection of Borrelia species. The analytical performance of the terL-targeting qPCR (referred to as Ter-qPCR) was thoroughly evaluated, and the test was shown to be able to detect one single Borrelia cell from blood samples. The diagnostic potential was evaluated using a set of blood and serum samples collected from healthy volunteers and individuals who were clinically diagnosed with LD.

In summary, we demonstrate that a quantitative phage-based PCR has the potential to change the diagnosis of LD from blood samples. This approach of detecting bacteria-specific phages may be applicable to infections other than LD such as sepsis caused by Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa etc. (Minasyan, 2019), as long as suitable phages are identifiable.

Results and Discussion

Each Borrelia species has a distinct amount of species specific variation in its prophage sequences; thus these prophages can be used as a proxy to identify the bacteria because of the tight correlation between them and the exact prophages found in each Borrelia host. As there are multiple prophages per Borrelia cell, the detectable signal is higher for prophages than bacteria. Furthermore, evidence suggests that Borrelia prophages can be released outside the Borrelia cells following encounters with stressors such as antibiotics (Eggers and Samuels, 2000). In this study, we confirmed that Borrelia prophages can escape from the bacterial host cell in a spontaneous manner. Taking advantage of the multicopy and free movement of Borrelia prophages, the approach to target prophages instead of bacteria will bypass the cryptic and tissue-bound feature that typifies human Borrelia infections (Liang et al., 2020). Thus, we have a greater chance of detecting the prophages in blood even when the bacteria may not be present or present in extremely low numbers. In this sense, prophages are somewhat analogous to Borrelia ‘footprints’.

(See link for full article)

_______________________

**Comment**

Important excerpt:

Borrelia Strains and Cultures

The Borrelia strains used in this study are listed in Table 1.

  • Ten strains were provided by Professor Sven Bergström, Department of Molecular Biology, Umea University, Sweden. Seven strains were purchased from the Pasteur Institute and DSMZ (German Collection of Microorganisms and Cell Cultures GmbH).
  • Two strains were provided by the Center for Disease Control and Prevention (CDC), United States, and
  • two by Cecilia Hizo-Teufel from the German National Reference Centre for Borrelia

For more: 

Lyme Disease Patient With Permanent Tinnitus & Hearing Loss

https://danielcameronmd.com/lyme-disease-tinnitus-hearing-loss/  Podcast here

LYME DISEASE PATIENT WITH PERMANENT TINNITUS AND HEARING LOSS

lyme-disease-tinnitus

Hello, and welcome to another Inside Lyme Podcast. I am your host Dr. Daniel Cameron. I find that the best way to get to know Lyme disease is through reviewing actual cases. In this episode, I’ll be discussing a case involving a 46-year-old man with Lyme disease who developed permanent tinnitus and hearing loss.

Jozefowicz-Korczynska and colleagues first described this case in the journal Frontiers in Neurology in 2019.

A 46-year-old male farmer was hospitalized with a “sudden onset of tinnitus and hearing loss in the left ear, dizziness, severe balance instability, and gait ataxia,” the authors write.  (Gait ataxia consists of lack of voluntary coordination of muscle movements.)

Doctors initially suspected vestibular schwannoma, which is a benign tumor of the 8th nerve (also referred to as an acoustic nerve) that affects hearing and balance. But diagnostic testing was normal.

However, a Western blot test and spinal tap revealed the patient was positive for Lyme disease. He was treated with a 3-week course of oral doxycycline, but his dizziness and gait problems persisted.

The patient did not receive any additional oral or intravenous antibiotics. Instead, he was referred to a Balance Disorders Unit for vestibular evaluation.

“Upon his examination, the patient presented with severe gait disturbance and imbalance,” the authors write.

Audiology tests indicated the man had mild to moderate sensory-neural hearing loss in both ears.

He underwent vestibular rehabilitation therapy for 10 consecutive days which significantly improved his balance. But his hearing loss and tinnitus remained.

“Unfortunately, the antibiotic therapy was not successful in decreasing hearing loss or tinnitus, suggesting permanent damage to the hearing nerve and cochlea,” write the authors.

Another study by Logigian et al. from Tufts University of Medicine found that 4 out of 27 patients with chronic neurologic Lyme disease presented with hearing loss and tinnitus.2

Meanwhile, a study in Poland revealed that 162 out of 216 patients with tick-borne diseases had otolaryngological (ear, nose, throat) symptoms.

“The most common complaint was tinnitus (76.5%) accompanied by vertigo and dizziness (53.7%), headache (39%), and unilateral sensorineural hearing loss (16.7%).”3

The following questions are discussed in this episode:

  1. Initially, doctors suspected vestibular schwannoma. Can you explain this condition and why it was considered as a possible diagnosis?
  2. The patient was tested for Lyme disease. His symptoms were not typical for Lyme, so why was testing ordered?
  3. Would more than a three-week course of doxycycline have helped resolve the man’s tinnitus and hearing loss?
  4. How common is hearing loss, vertigo, tinnitus, and gait impairment in Lyme disease?
  5. What are other causes of tinnitus and hearing loss?
  6. Why was the patient referred to a balance disorder unit and was his treatment successful?
  7. There have been several cases of hearing loss reported in the literature. Can you discuss the Tufts University and Poland studies featured in one of your blogs?
    Thanks for listening to another Inside Lyme Podcast. You can read more about these cases in my show notes and on my website @DanielCameronMD.com. As always, it is your likes, comments, reviews, and shares that help spread the word about Lyme disease. Until next time on Inside Lyme.

Please remember that the advice given is general and not intended as specific advice as to any particular patient. If you require specific advice, then please seek that advice from an experienced professional.

Inside Lyme Podcast Series

This Inside Lyme case series will be discussed on my Facebook and made available on podcast and YouTube.  As always, it is your likes, comments, and shares that help spread the word about this series and our work. If you can, please leave a review on iTunes or wherever else you get your podcasts.

References:
  1. Jozefowicz-Korczynska M, Zamyslowska-Szmytke E, Piekarska A, Rosiak O. Vertigo and Severe Balance Instability as Symptoms of Lyme Disease-Literature Review and Case Report. Front Neurol. 2019 Nov 12;10:1172.
  2. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990;323(21):1438-1444.
  3. Sowula K, Skladzien J, Szaleniec J, Gawlik J. Otolaryngological symptoms in patients treated for tick-borne diseases. Otolaryngol Pol. 2018;72(1):30-34.

_______________________

For more:

Tuttle’s Letter to CDC Director: “Will You Do the Right Thing & Upgrade Lyme Disease to Highest Alert & Promote a Manhattan Project to Find a Cure?”

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/u/

Certified Mail to Rochelle Walensky, MD Director of The US Centers for Disease Control

MAR 21, 2021 — 

The maniacal suppression and censorship of evidence that we have been dealing with an antibiotic resistant/tolerant superbug has left hundreds of thousands if not millions in a debilitated state. The following letter and attachments have been forwarded to the New Hampshire Study Group Members and NH Governor Chris Sununu.

“In the fullness of time, the main stream handling of chronic Lyme disease will be viewed as one of the most shameful episodes in the history of medicine because elements of academic medicine, elements of government and virtually the entire insurance industry have colluded to deny a disease.”  –Dr. Kenneth Liegner

Next Zoom meeting for the NH Lyme Study Commission:03/26/2021 9:00 AM

http://www.gencourt.state.nh.us/statstudcomm/details.aspx?id=1515&rbl=1&txtbillnumber=hb490

———- Original Message ———-

From: CARL TUTTLE <runagain@comcast.net>
To: All members of the NH Lyme Study Commission
Cc: NH Governor Chris Sununu
Date: 03/19/2021 4:57 PM
Subject: Certified Mail to Rochelle Walensky, MD Director of The US Centers for Disease Control

To members of the Lyme Study Commission,

I would like to add the attached communication as a topic for discussion at a future meeting and have copied all committee members so they can review the documents prior to the meeting.

Please reserve any discussion of these documents until our next scheduled Zoom meeting.

Respectfully submitted,

Carl Tuttle

The following letter was sent VIA Certified Mail to Rochelle Walensky, MD Director of The US Centers for Disease Control:

Tracking Number: 70201290000232782577

https://tools.usps.com/go/TrackConfirmAction?tRef=fullpage&tLc=2&text28777=&tLabels=70201290000232782577%2C&tABt=false

Your item was picked up at a postal facility at 9:32 am on March 15, 2021 in ATLANTA, GA 30329.

Status: Delivered

March 15, 2021 at 9:32 am

Delivered, Individual Picked Up at Postal Facility

ATLANTA, GA 30329

NEW HAMPSHIRE COMMISSION TO STUDY TESTING OF LYME AND OTHER TICK-BORNE DISEASES

NOTE: The general public only has access to serology for Lyme disease which cannot be used to gauge treatment failure or success but in 1991. The Centers for Disease Control in Fort Collins, Colorado identified chronic persistent Lyme disease in a patient who was previously treated with extensive oral and IV antibiotics.

Cover letter to Dr. Walensky VIA Certified Mail:

Dr. Walensky’s public email address as obtained from the HHS online Directory:  aux7@cdc.gov

Mar 10, 2021

Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30329
Attn: Rochelle Walensky, MD Director

Dear Dr. Walensky,

New Hampshire has one of the highest rates of Lyme disease in the country. Patient testimony all across America is describing a disease that is destroying lives, ending careers while leaving its victim in financial ruin. (read the written comments posted to the TBDWG website)

The attached email sent to you on Feb 17, 2021 has been shared with all members of New Hampshire Governor Chris Sununu’s Lyme Disease Study Commission. Included in this correspondence is the positive CDC culture report for Vicki Logan who had been treated for Lyme disease with extensive IV and oral antibiotics.

The CDC had culture confirmation that we were dealing with an antibiotic resistant/tolerant superbug in 1991 when Borrelia burgdorferi was grown from the cerebrospinal fluid of Dr. Kenneth Liegner’s patient Vicki Logan at the Centers for Disease Control in Fort Collins, Colorado.

You are in a position to right the wrongs that your predecessors have chosen to ignore.

Will you do the right thing and upgrade Lyme disease to Highest Alert and promote a Manhattan Project to find a cure for this antibiotic resistant/tolerant superbug?

A response to this inquiry is requested.

Sincerely,

Carl Tuttle
Hudson, NH 03051

Member of the NH Lyme Disease Study Commission
http://www.gencourt.state.nh.us/statstudcomm/details.aspx?id=1515&rbl=1&txtbillnumber=hb490

Cc: All members of the NH Lyme Disease Study Commission,
Governor Chris Sununu

Attachments:

1. Email sent to Dr. Walensky on Feb 17, 2021 (Personal Dropbox storage area)

https://www.dropbox.com/s/l06t9qm1fhfqzl9/Email%20to%20Walensky%20Feb%2017%20%202021.docx?dl=0

2. Positive culture report for Lyme patient Vicki Logan (Personal Dropbox storage area)

https://www.dropbox.com/s/vthfdpn7gv8bne2/Logan%20CDC%20Fort%20Collins%20Positive%20CSF%20%20Culture%20Report.JPG?dl=0

CDC Director
___________________________
 
**Comment**
 
Interestingly, Walensky fears “impeding doom”  about COVID.  
 
Excerpt:
 
At the start of her tenure, Walensky said she had pledged to always tell the truth even if it wasn’t something Americans wanted to hear.

“I’m going to pause here,” she said, and her voice began to shake.

“I’m going to lose the script and I’m going to reflect on the recurring feeling I have of impending doom,” said Walensky, her eyes growing wider and starting to shine.

“We have so much to look forward to, so much promise and potential of where we are, and so much reason for hope. But right now I’m scared,” she said.

Let’s see if Walensky equally fears Lyme/MSIDS, the number ONE vector-borne disease that has been denied and ignored by our government and our health ‘authorities’ for over 40 years, with thousands of patients being told their symptoms are “all in their head.”
Let’s see if she’s willing to “tell the truth” about tick-borne illness even if it isn’t something people want to hear.

I’m not holding my breath.